Log in
Barbiturate anticonvulsant

Phenobarbital

Phenobarbital is a long-acting barbiturate that acts as a broad-spectrum anticonvulsant and sedative-hypnotic agent. It enhances GABAergic inhibition in the central nervous system and is primarily used for seizure disorders, particularly in neonatal seizures and refractory epilepsy. The most testable fact is that phenobarbital is a potent inducer of hepatic cytochrome P450 enzymes, leading to numerous clinically significant drug interactions.

Practice questionsHigh-yield facts
Drug classBarbiturate anticonvulsant and sedative-hypnotic
MechanismEnhances GABA-A receptor activity, prolongs chloride channel opening
Main usesSeizures, neonatal seizures, status epilepticus
Key adverse effectSedation, cognitive impairment, respiratory depression
7 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Phenobarbital enhances inhibitory neurotransmission through multiple mechanisms at the GABA-A receptor complex. It acts as a positive allosteric modulator, binding at a site distinct from the benzodiazepine binding site, and prolongs the duration of chloride channel opening. At higher concentrations, phenobarbital can directly activate GABA-A receptors even in the absence of GABA.

Beyond GABAergic effects, phenobarbital also inhibits excitatory neurotransmission by blocking AMPA-type glutamate receptors and voltage-gated calcium channels. These combined actions result in membrane hyperpolarization, decreased neuronal excitability, and elevation of the seizure threshold. The anticonvulsant effect occurs at doses lower than those required for hypnosis, allowing therapeutic use in epilepsy management.

Phenobarbital is a potent inducer of hepatic microsomal enzymes, particularly cytochrome P450 isoforms CYP2C9, CYP2C19, and CYP3A4. This enzyme induction increases the metabolism of numerous endogenous and exogenous substances, leading to clinically significant drug interactions and altered pharmacokinetics of co-administered medications.

High-yield for exams
  • Phenobarbital enhances GABA-A receptor activity and blocks glutamate receptors, providing broad-spectrum anticonvulsant effects
  • Potent inducer of CYP2C9, CYP2C19, and CYP3A4, causing numerous drug interactions including reduced oral contraceptive efficacy
  • Very long half-life (80-100 hours in adults) allows once-daily dosing but requires weeks to reach steady state
  • Therapeutic serum concentration range is 15-40 mcg/mL; therapeutic drug monitoring is recommended
  • Absolutely contraindicated in porphyria as it can precipitate life-threatening acute attacks
  • Physical dependence develops with chronic use; abrupt discontinuation causes withdrawal seizures and must be avoided
  • First-line treatment for neonatal seizures due to established safety profile in this population
  • Common adverse effects include sedation, cognitive impairment, and paradoxical hyperactivity in children

Indications

Phenobarbital is indicated for the treatment of various seizure disorders and has specific applications where its long half-life and broad-spectrum activity are advantageous.

Epilepsy

  • Generalized tonic-clonic seizures: effective as monotherapy or adjunctive treatment
  • Focal seizures: second-line or adjunctive therapy
  • Neonatal seizures: often first-line treatment in newborns due to safety profile
  • Status epilepticus: used when benzodiazepines and other agents fail
  • Febrile seizures: prophylaxis in selected high-risk pediatric patients

Other Uses

  • Sedation: preoperative sedation and anxiolysis
  • Hyperbilirubinemia: enzyme induction to increase bilirubin conjugation
  • Withdrawal syndromes: management of alcohol or sedative-hypnotic withdrawal

Phenobarbital remains widely used in resource-limited settings due to its low cost, long half-life allowing once-daily dosing, and availability in oral and injectable formulations. In developed countries, it is often reserved for refractory cases or specific populations such as neonates where newer anticonvulsants lack safety data.

Pharmacokinetics

Phenobarbital exhibits predictable pharmacokinetics that influence its clinical use and monitoring requirements.

Absorption: Well absorbed orally with bioavailability of 80-100%. Peak plasma concentrations occur 1-3 hours after oral administration. Intramuscular and intravenous routes are also available.

Distribution: Widely distributed throughout body tissues with a volume of distribution of 0.5-0.6 L/kg. Approximately 40-60% protein bound, primarily to albumin. Crosses the blood-brain barrier readily and achieves therapeutic CNS concentrations. Crosses the placenta and is excreted in breast milk.

Metabolism: Hepatic metabolism via cytochrome P450 enzymes, primarily CYP2C19 and CYP2C9, to inactive metabolites. Approximately 25% is excreted unchanged in urine. Phenobarbital induces its own metabolism with chronic use.

Elimination: Extremely long half-life of 50-140 hours in adults (average 80-100 hours), shorter in children (40-70 hours), and prolonged in neonates (100-500 hours). Renal excretion is pH-dependent; alkalinization of urine enhances elimination. Steady-state concentrations are achieved after 2-3 weeks of regular dosing.

Therapeutic drug monitoring is recommended with target serum concentrations of 15-40 mcg/mL for seizure control. The long half-life allows once-daily dosing but also means that dose adjustments require weeks to reach new steady-state levels.

Adverse effects

Phenobarbital produces dose-dependent adverse effects affecting multiple organ systems, with CNS depression being most prominent.

Common Adverse Effects

  • CNS depression: sedation, drowsiness, lethargy, cognitive impairment
  • Behavioral changes: irritability, hyperactivity (paradoxical in children), mood disturbances
  • Motor effects: ataxia, incoordination, nystagmus
  • Cognitive impairment: memory problems, decreased attention, learning difficulties
  • Tolerance: develops to sedative but not anticonvulsant effects

Serious Adverse Effects

  • Respiratory depression: dose-dependent, risk increased with other CNS depressants
  • Cardiovascular depression: hypotension, bradycardia with rapid IV administration
  • Megaloblastic anemia: due to folate deficiency from enzyme induction
  • Osteomalacia and rickets: increased vitamin D metabolism
  • Stevens-Johnson syndrome and toxic epidermal necrolysis: rare but serious cutaneous reactions
  • Hepatotoxicity: rare idiosyncratic reactions

Dependence and Withdrawal

Chronic use leads to physical dependence. Abrupt discontinuation causes withdrawal syndrome characterized by anxiety, tremor, insomnia, seizures, delirium, and potentially life-threatening cardiovascular collapse. Withdrawal seizures may occur 2-8 days after cessation. Tapering over weeks to months is mandatory when discontinuing therapy.

Pediatric Considerations

Children may experience paradoxical hyperactivity, irritability, and sleep disturbances. Cognitive effects on learning and development are concerns with long-term use.

Contraindications and warnings

Absolute Contraindications

  • Known hypersensitivity to barbiturates
  • Manifest or latent porphyria (acute intermittent, variegate, hereditary coproporphyria)
  • Severe respiratory insufficiency or airway obstruction
  • Severe hepatic impairment
  • History of barbiturate abuse or addiction

Warnings and Precautions

Suicide risk: Antiepileptic drugs, including phenobarbital, increase the risk of suicidal thoughts and behavior. Monitor patients for emergence or worsening of depression, suicidal ideation, or unusual behavior changes.

Respiratory depression: Use with extreme caution in patients with compromised respiratory function, including COPD, sleep apnea, or neuromuscular disorders. Avoid concurrent use with other respiratory depressants.

Hepatic and renal impairment: Dose reduction required in significant hepatic or renal dysfunction. Monitor drug levels closely.

Pregnancy: Phenobarbital is associated with increased risk of congenital malformations, particularly cardiac defects and cleft palate. However, uncontrolled seizures pose significant maternal and fetal risks. Use only if potential benefit justifies the risk. Neonates born to mothers taking phenobarbital may experience withdrawal symptoms and require monitoring. Supplemental vitamin K is recommended in the final weeks of pregnancy to prevent hemorrhagic disease of the newborn.

Elderly patients: Increased sensitivity to CNS and respiratory depression. Higher risk of falls, confusion, and paradoxical excitement. Use lowest effective dose.

Abrupt discontinuation: Never discontinue suddenly due to risk of status epilepticus and severe withdrawal syndrome. Taper gradually over weeks to months.

Drug interactions

Phenobarbital has extensive drug interactions due to its potent enzyme-inducing properties and additive CNS depressant effects.

Enzyme Induction Effects

Phenobarbital induces CYP2C9, CYP2C19, CYP3A4, and other metabolic enzymes, significantly reducing levels of:

  • Anticoagulants: warfarin (requires dose adjustment and INR monitoring)
  • Anticonvulsants: lamotrigine, valproate, carbamazepine, tiagabine
  • Hormonal contraceptives: reduced efficacy, alternate contraception recommended
  • Corticosteroids: decreased levels of prednisone, dexamethasone
  • Immunosuppressants: cyclosporine, tacrolimus (requires monitoring)
  • Antiretrovirals: protease inhibitors, NNRTIs
  • Cardiovascular drugs: calcium channel blockers, beta-blockers, digoxin
  • Antimicrobials: doxycycline, metronidazole, itraconazole
  • Psychotropics: TCAs, SSRIs, antipsychotics, benzodiazepines

Enzyme induction takes 1-2 weeks to develop fully and persists for 2-4 weeks after phenobarbital discontinuation.

CNS Depression

Additive sedation and respiratory depression with:

  • Alcohol
  • Benzodiazepines
  • Opioids
  • Other sedative-hypnotics
  • First-generation antihistamines
  • Antipsychotics

Specific Drug Interactions

Valproate: increases phenobarbital levels by inhibiting metabolism; phenobarbital decreases valproate levels through enzyme induction. Monitor levels of both drugs.

MAO inhibitors: prolong phenobarbital effects.

Phenytoin: complex bidirectional interaction; both drugs may increase or decrease levels of the other unpredictably.

Vitamin K antagonists: significantly reduced anticoagulant effect requiring dose escalation.

Consult drug interaction resources when adding or discontinuing phenobarbital in patients on multiple medications. Dose adjustments and therapeutic drug monitoring are frequently necessary.

Clinical pearls

  • Therapeutic drug monitoring is essential due to narrow therapeutic index and wide inter-patient variability. Target serum concentrations are 15-40 mcg/mL, though some patients require higher levels for seizure control.
  • Loading doses can be used in status epilepticus, but intravenous administration must be slow to avoid cardiovascular and respiratory depression.
  • Tolerance develops to sedative effects within days to weeks, but anticonvulsant efficacy is generally maintained. Patients should be counseled that initial drowsiness typically improves.
  • Paradoxical hyperactivity in children is common and may necessitate switching to alternative anticonvulsants. Behavioral monitoring is important in pediatric patients.
  • Enzyme induction begins within days but reaches maximum effect at 2-3 weeks. When discontinuing phenobarbital, remember that enzyme activity returns to baseline slowly, affecting other drug levels for weeks.
  • Neonatal treatment: phenobarbital remains first-line for neonatal seizures due to extensive safety data, though efficacy is modest. Higher loading doses are sometimes used per institutional protocols.
  • Pregnancy management: if phenobarbital must be continued, use the lowest effective dose, provide high-dose folic acid supplementation, and administer vitamin K to the mother before delivery.
  • Cost-effectiveness: in low-resource settings, phenobarbital's extremely low cost and once-daily dosing make it a practical choice despite tolerability issues.
  • Withdrawal protocol: taper gradually by reducing the daily dose in small decrements over extended periods. Faster tapers risk withdrawal seizures, even in patients without epilepsy.
  • Porphyria screening: obtain family and personal history before initiating treatment, as barbiturates are absolutely contraindicated in porphyria and can precipitate life-threatening acute attacks.
  • Drug level timing: measure trough levels just before the next dose. Due to the long half-life, levels can be drawn any time after steady state (2-3 weeks), but consistency in timing aids interpretation.
  • Urine alkalinization: in phenobarbital overdose, urinary alkalinization with sodium bicarbonate enhances renal elimination by ion trapping, as phenobarbital is a weak acid (pKa 7.4).
Mnemonic

BARBITURATE for adverse effects: Behavioral changes, Ataxia, Respiratory depression, Birth defects, Interactions (P450 induction), Tolerance, Urinary alkalinization (overdose treatment), Respiratory depression, Addiction potential, Tapering required, Enzyme induction

Practice questions

1. A 6-year-old boy with generalized tonic-clonic seizures has been treated with phenobarbital for 3 months. His seizures are well controlled, but his teacher reports that he has become increasingly irritable and hyperactive in class, and his academic performance has declined. His parents confirm similar behavior at home. Physical examination shows no focal neurological deficits. Which of the following is the most appropriate next step in management?

Answer: D. This child is experiencing paradoxical hyperactivity and cognitive effects, common adverse effects of phenobarbital in pediatric patients. Since seizures are well controlled but quality of life is significantly impaired, switching to an alternative anticonvulsant with better tolerability is most appropriate. Increasing the dose would worsen behavioral symptoms. Checking levels might be reasonable but would not address the core problem that phenobarbital is causing unacceptable adverse effects despite therapeutic efficacy. While behavioral support could help, removing the causative agent (phenobarbital) is the definitive solution.

2. A 28-year-old woman with epilepsy controlled on phenobarbital for 5 years presents for preconception counseling. She takes oral contraceptive pills and has been seizure-free for 3 years. She asks about pregnancy planning. Which of the following is the most important counseling point regarding her current medications?

Answer: B. Phenobarbital is a potent inducer of cytochrome P450 enzymes, which significantly increases metabolism of oral contraceptives and reduces their efficacy. This patient is at risk for contraceptive failure and unplanned pregnancy. Alternative contraception methods should be recommended. While phenobarbital does carry teratogenic risks, abrupt discontinuation can precipitate status epilepticus, which poses greater fetal risk than controlled seizures. Valproate has the highest teratogenic risk among anticonvulsants and should be avoided in women of childbearing potential. Proper counseling includes discussing both the contraceptive interaction and the need for planned pregnancy with medication optimization under specialist supervision.

3. A 45-year-old man with alcohol use disorder is admitted for acute alcohol withdrawal. He is started on phenobarbital for seizure prophylaxis and symptom control. On hospital day 3, he develops fever, severe abdominal pain, muscle weakness in his legs, and confusion. Urine is noted to be dark red. Laboratory studies show hyponatremia. Which of the following best explains his presentation?

Answer: B. This patient has classic features of acute intermittent porphyria: severe abdominal pain, neurological symptoms (weakness, confusion), hyponatremia, and dark urine (due to porphobilinogen). Barbiturates are absolutely contraindicated in porphyria because they induce ALA synthase, increasing demand for heme synthesis and causing accumulation of toxic porphyrin precursors when enzymatic defects are present. Phenobarbital overdose would cause CNS and respiratory depression, not these symptoms. Delirium tremens typically occurs earlier and features autonomic hyperactivity. While rhabdomyolysis causes dark urine, it would show elevated creatine kinase and myoglobinuria, not the constellation of abdominal pain and neuropathy. This case highlights the critical importance of screening for porphyria before administering barbiturates.

Frequently asked questions

How does phenobarbital work?

Phenobarbital works by enhancing GABA-A receptor activity, which increases inhibitory neurotransmission in the brain. It prolongs chloride channel opening time and at higher concentrations can directly activate GABA-A receptors. Additionally, it blocks AMPA glutamate receptors and voltage-gated calcium channels, reducing neuronal excitability. These combined mechanisms raise the seizure threshold and produce anticonvulsant effects at doses lower than those required for sedation.

What are the side effects of phenobarbital?

Common side effects include sedation, drowsiness, cognitive impairment, ataxia, and memory problems. In children, paradoxical hyperactivity and irritability may occur. Serious adverse effects include respiratory depression, particularly when combined with other CNS depressants, cardiovascular depression with rapid IV administration, and rare but severe skin reactions like Stevens-Johnson syndrome. Long-term use can cause vitamin deficiencies leading to megaloblastic anemia and osteomalacia. Physical dependence develops with chronic use, and abrupt discontinuation causes potentially life-threatening withdrawal syndrome.

Is phenobarbital a controlled substance?

Yes, phenobarbital is a Schedule IV controlled substance in the United States under the Controlled Substances Act. This classification reflects its potential for abuse and physical dependence, though it is lower than Schedule II or III substances. Despite controlled status, phenobarbital remains widely prescribed for legitimate medical uses in epilepsy management. Prescribers must follow regulations regarding prescription requirements, refills, and record-keeping when dispensing barbiturates.

Why is phenobarbital contraindicated in porphyria?

Phenobarbital is absolutely contraindicated in acute porphyrias because it induces delta-aminolevulinic acid (ALA) synthase, the rate-limiting enzyme in heme synthesis. This induction increases demand for heme production but in patients with porphyria, enzymatic defects in the heme synthesis pathway cause accumulation of toxic porphyrin precursors. Barbiturate administration can precipitate acute porphyric attacks characterized by severe abdominal pain, neuropathy, psychiatric symptoms, and potentially fatal cardiovascular and respiratory complications. Even a single dose can trigger an attack in susceptible individuals.

Phenobarbital vs phenytoin — what is the difference?

Both are older anticonvulsants but differ significantly in mechanism and properties. Phenobarbital enhances GABA transmission and has a very long half-life (80-100 hours), allowing once-daily dosing, while phenytoin blocks sodium channels and has a shorter half-life (12-36 hours). Phenobarbital causes more sedation and cognitive effects, whereas phenytoin commonly causes gingival hyperplasia, hirsutism, and coarsened facial features. Both are potent enzyme inducers causing drug interactions. Phenytoin exhibits zero-order kinetics at therapeutic doses, making dosing adjustments challenging, while phenobarbital follows first-order kinetics. Phenobarbital is preferred for neonatal seizures, while phenytoin is often used for status epilepticus in adults.

Conditions it is used for

EpilepsyGeneralized tonic-clonic seizuresFocal seizuresNeonatal seizuresStatus epilepticusFebrile seizuresNeonatal hyperbilirubinemiaAlcohol withdrawal syndrome
PrimidonePhenytoinCarbamazepineValproateLevetiracetamLamotrigineDiazepamLorazepam

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N03AA02

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.